# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-058967
Filing Date
2025-04-28
Accepted
2025-04-28 08:03:03
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | copy_of_mura-defa14a-202.htm | DEFA14A | 28664
2 | GRAPHIC | img86461489_0.jpg | GRAPHIC | 1247987
3 | GRAPHIC | img86461489_1.jpg | GRAPHIC | 335973
| Complete submission text file | 0000950170-25-058967.txt |  | 2209132

Mailing Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380
Business Address 10 EARLSFORT TERRACE DUBLIN 2 L2 D02 T380 353 1 905 8020
Mural Oncology plc (Filer) CIK: 0001971543 (see all company filings)

EIN.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-41837 | Film No.: 25876002
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)